Liu, Wenli, Aaron Schoenkerman, and William L. Lowe, Jr. Activation of members of the mitogen-activated protein kinase family by glucose in endothelial cells. Am J Physiol Endocrinol Metab 279: E782-E790, 2000.-To better understand the molecular mechanisms for hyperglycemiainduced proatherogenic changes in endothelial cells, the effect of high glucose on activation of members of the mitogenactivated protein kinase (MAPK) family, including c-Jun NH 2 -terminal kinase (JNK), extracellular signal-regulated kinase (ERK)-1, -2, and -5, and p38 kinase, was examined in bovine pulmonary artery endothelial cells (PAEC). Glucose, fructose, and raffinose induced a concentration-dependent decrease in PAEC growth. Addition of 25 mM glucose, fructose, or raffinose to normal growth medium stimulated an approximately twofold increase in JNK1 activity that was maximal after 24 h, whereas only glucose markedly increased ERK5 activity. Neither ERK1/2 nor p38 kinase activity was increased by glucose, fructose, or raffinose. The antioxidant N-acetylcysteine partially abrogated the glucoseinduced increase in ERK5 activity but had no effect on the increase in JNK1 activity. In contrast, azaserine, which prevents increased flux through the hexosamine pathway, decreased glucose-induced JNK1 activity but had no effect on fructose-or raffinose-induced JNK1 activity. Consistent with this finding, glucosamine stimulated a 2.4-fold increase in JNK1 activity and reproduced the inhibitory effect of glucose on PAEC growth. In summary, glucose activates different members of the MAPK family in PAEC via distinct mechanisms. Moreover, the correlation between the ability of different sugars to activate JNK1 and inhibit cell growth suggests that activation of this signaling pathway may contribute to the growth inhibitory effect of glucose in endothelial cells.
CARDIOVASCULAR DISEASE is the leading cause of death in adults with diabetes mellitus (9) . Compared with other individuals with equivalent risk factors, people with diabetes have a four-to fivefold increase in mortality from vascular disease (9) . The factors that are responsible for this increased risk of cardiovascular disease are not known, but studies in patients with types 1 and 2 diabetes have demonstrated that good metabolic control is able to prevent early changes of atherosclerosis and decrease the risk of coronary heart disease events and deaths (15, 22) . These data suggest that hyperglycemia contributes to the increased risk of cardiovascular disease, but whether this is secondary to a direct effect of glucose on vascular cells or an indirect effect secondary to the modification of other risk factors is not known.
Previous studies have demonstrated that glucose has effects on endothelial cells that are proatherogenic. Prominent among these effects is the inhibition of endothelial cell growth by hyperglycemia (7, 10, 17, 26, 34) . In human umbilical vein endothelial cells, the inhibition of cell growth is secondary to delayed passage through the cell cycle (26) . To date, however, the mechanism for the effect of glucose on endothelial cell growth has not been clearly defined. One recent study suggested that the inhibition of proliferation was secondary to increased production of transforming growth factor-␤, with a subsequent decrease in hepatocyte growth factor production, whereas others have suggested that sorbitol accumulation and/or the generation of reactive oxygen species contributes to the inhibition of endothelial cell proliferation by glucose (7, 10, 17) .
Regardless of the mechanism, it is likely that the effect of glucose is mediated by proximal signaling events that stimulate downstream effects. To date, the nature of these proximal signaling events remains poorly defined. The mitogen-activated protein kinase (MAPK) pathway consists of a group of interconnecting protein kinase cascades that link signals at the plasma membrane to nuclear events and are important for both stimulating and inhibiting cell proliferation (23, 25, 42) . Four different families of MAPKs that are linked to different signals at the plasma membrane and have different substrate specificities have been described, including extracellular signal-regulated kinase (ERK)-1 and -2, c-Jun NH 2 -terminal kinases (JNKs), p38 kinases, and big MAPK 1 or ERK5 (23, 25, 42) . ERK1 and -2 are activated primarily in response to proliferative stimuli (30, 42) , whereas the other MAPKs are activated primarily in response to inflammatory and stressful stimuli, including oxidant and osmotic stresses (1, 8, 23, 24) . Activation of the JNKs and p38 kinases is associated with inhibition of cell growth in some cell types, although this effect appears to be cell type specific (8, 23, 24) . The biological role of the more recently defined ERK5 is less clear.
Given the critical role that the MAPKs play in the regulation of cell growth and the described effects of glucose on endothelial cell growth, the studies described herein were designed to address whether glucose alters MAPK activity in endothelial cells and the metabolic pathways that account for glucose-induced effects on MAPK activity.
MATERIALS AND METHODS
Cell culture. Bovine pulmonary artery endothelial cells (PAECs) were provided by Drs. Mark Yorek and Robert Bar (University of Iowa). The cells were maintained in 75-cm 2 flasks in low-glucose (5.5 mM glucose) DMEM supplemented with 10% fetal bovine serum (FBS), 2 mM L-glutamine, 3.7 gm/l sodium bicarbonate, penicillin (50 U/ml), and streptomycin (50 U/ml) at 37°C in 5% CO 2 . Upon reaching confluence, the cells were replated at a dilution of 1:4. Cells between passages 5 and 15 were used for all studies.
Cell growth assay. For cell growth assays, PAEC were plated onto 24-well plates at a density of 5 ϫ 10 3 cells/well and maintained for 24 h in the low-glucose DMEM ϩ 10% FBS described above. At that time, the medium was changed and replaced with either low-glucose DMEM ϩ 10% FBS or low-glucose DMEM ϩ 10% FBS supplemented with increasing concentrations of glucose, fructose, or raffinose. After being maintained in the test media for 24, 48, or 72 h, cells were collected using trypsin and resuspended in Isoton II (Coulter, Miami, FL). Visual inspection of the plates was used to ensure that all cells had been released with trypsin. The number of cells per well was determined using a Coulter counter (Beckman Coulter, Fullerton, CA).
MAPK immune complex assays. For the kinase assays, cells were plated at a density of 5 ϫ 10 5 cells/75-cm 2 plate and maintained for 24 h in low-glucose DMEM ϩ 10% FBS for 24 h. For assays performed in the presence of FBS, medium was changed after 24 h and replaced with either low-glucose DMEM ϩ 10% FBS or low-glucose DMEM ϩ 10% FBS supplemented with 25 mM glucose, fructose, or raffinose. For assays performed in serum-free medium, cells were transferred to low-glucose DMEM ϩ 0.25% BSA for 24 h. This medium was then replaced with either low-glucose DMEM ϩ 0.25% BSA or low-glucose DMEM ϩ 0.25% BSA supplemented with either 25 mM glucose, fructose, or raffinose.
Antibodies directed against JNK1, p38 kinase, ERK5, and ERK2 were obtained from Santa Cruz Biotechnology (Santa Cruz, CA). The substrate protein for the JNK immune complex assay was a GST-c-Jun fusion protein. To generate a cDNA for the synthesis of this fusion protein, a fragment of DNA encoding the amino-terminal 81 amino acids of c-Jun was amplified using the PCR with a rat c-jun cDNA as template DNA. The amplified fragment, the identity of which was confirmed by DNA sequencing, was purified and cloned into pGEX4T-1 (Amersham Pharmacia Biotech, Piscataway, NJ) in frame with the GST gene. The resulting fusion protein (GST-c-Jun81) was purified from bacterial lysates using glutathione-agarose beads according to the manufacturer's instructions (Amersham Pharmacia Biotech). The substrate for the p38 kinase assay was GST-ATF2. The GST-ATF2 fusion protein was prepared using the plasmid pGST-ATF2 (kindly provided by Dr. Roger Davis, Howard Hughes Medical Institute, University of Massachusetts Medical School), as described above. The substrate for the ERK2 and ERK5 assays was myelin basic protein (Sigma, St. Louis, MO).
ERK2 assays were performed using an immune complex assay as described previously (27) . The JNK1 immune complex assay was performed using a previously described method (40) . Briefly, cells were maintained in the different media for the indicated period of time and solubilized in lysis buffer [20 mM Tris (pH 7.4), 1% Triton X-100, 10% glycerol, 137 mM NaCl, 2 mM EDTA, 25 mM ␤-glycerophosphate, 1 mM sodium vanadate, 2 mM sodium pyrophosphate, 10 g/ml leupeptin, and 1 mM phenylmethanesulfonyl fluoride (PMSF)]. The protein concentration of the cell lysate was determined using the Coomassie blue protein assay (Bio-Rad Laboratories, Richmond, CA). After clarification, 100-150 g of cell lysate protein were incubated for 2 h at 4°C with anti-JNK1 antibodies that had been prebound to protein A agarose beads. The beads were collected, washed, and resuspended in kinase buffer [25 mM HEPES (pH 7.4), 25 mM ␤-glycerophosphate, 25 mM MgCl 2 , 2 mM dithiothreitol (DTT), and 0.1 mM sodium orthovanadate]. The kinase reaction was initiated by adding 12.5 Ci of [␥-
32 P]ATP and 1 g of GST-c-Jun81 and was allowed to proceed for 30 min at 30°C. The reaction was terminated by the addition of Laemmli sample buffer. The proteins were eluted from the beads by heating at 95°C for 5 min and separated by SDS-PAGE on a 15% polyacrylamide gel. The resulting gel was dried and exposed to X-ray film or used in a STORM 860 PhosphorImager (Molecular Dynamics, Sunnyvale, CA) to calculate 32 P incorporation into GST-c-Jun81. All assays were performed in duplicate. Activity of p38 kinase also was determined as described above, except that anti-p38 kinase antibodies were bound to protein A agarose beads and GST-ATF2 was used as the substrate protein. For the ERK5 immune complex assay, the lysis buffer was as follows: 150 mM NaCl, 1% NP-40, 0.5% deoxycholate, 0.1% SDS, 50 mM Tris (pH 7.5), 1 M sodium orthovanadate, 2 mM sodium pyrophosphate, 1 mM PMSF, and 10 g/ml leupeptin. The ERK5 assay was performed as described above, except that the kinase buffer was 25 mM HEPES (pH 7.4), 10 mM MgCl 2 , 10 mM MnCl 2 , 1 mM DTT, and 15 M ATP. The reaction was initiated by adding 500 Ci/ml [␥-32 P]ATP and 167 g/ml myelin basic protein. The reaction was allowed to proceed for 30 min at 30°C and was terminated and analyzed as described above.
Western blot analysis. Western blots were probed with a polyclonal antibody directed against phospho-ERK1/2 (New England Biolabs, Beverly, MA) at a dilution of 1:1,000 or with a polyclonal antibody directed against ERK2 (Santa Cruz Biotechnology) at a dilution of 1:7,500.
For Western blot analyses, cell lysates were prepared in the cell lysis buffer used for the ERK5 assay, as described above, and protein content of the lysate was determined using the Coomassie blue protein assay. Forty micrograms of protein were then diluted 1:4 in sample buffer [62.5 mM Tris ⅐ HCl (pH 6.8), 10% glycerol, 2% SDS, 5% ␤-mercaptoethanol, and 1% bromophenol blue], boiled for 5 min, and size-separated using SDS-PAGE. Proteins were transferred to a polyvinylidene difluoride (PVDF) membrane using a semi-dry apparatus in transfer buffer (25 mM Tris, 192 mM glycine, and 20% methanol). For Western blot analysis, membranes were blocked in 20 mM Tris (pH 7.6), 137 mM NaCl, 0.1% Tween-20 (TBST), and 4% nonfat dry milk for 90 min at room temperature. Membranes were incubated for 90 min at 22°C in TBST containing nonfat milk and primary antibody, washed three times for 15 min at 22°C in TBST, and incubated for 90 min at room temperature in TBST containing nonfat dry milk and secondary antibody (1:7,500 dilution). After three washes in TBST, immunoreactive bands were detected using the enhanced chemiluminescence detection system from Amersham (Arlington Heights, IL), according to the manufacturer's instructions.
Statistical analysis. Values are reported as means Ϯ SE. P values were calculated using the one-way repeated-measures ANOVA with Tukey's pairwise multiple comparision procedure or the Kruskal-Wallis one-way ANOVA on ranks with Dunnett's pairwise multiple comparison procedure, as appropriate, by SigmaStat 2.0 software (Jandel, San Rafael, CA).
RESULTS
Effect of sugars on cell growth. Initial studies were performed to examine the effect of glucose on PAEC growth by growing cells in the presence of increasing concentrations of glucose ( Table 1) . Supplementation of normal growth medium (low-glucose DMEM ϩ 10% FBS) with additional glucose resulted in a concentration-dependent decrease in cell growth. After 1 day of treatment, addition of both 20 and 25 mM glucose resulted in a significant inhibition of cell growth, whereas treatment with additional concentrations of glucose as low as 10 mM (final concentration 15.5 mM) resulted in a significant inhibition of cell growth after 2 and 3 days of treatment. Supplementation of the medium with 25 mM glucose decreased PAEC growth by 20, 39, and 45% after treatment for 1, 2, and 3 days, respectively.
For comparison, the effect of two other sugars, raffinose and fructose, was examined. Raffinose is a trisaccharide that, unlike glucose, is unable to enter the cell and thus exerts an osmotic effect. Fructose is a monosaccharide that, like glucose, enters the cell and is converted to either fructose 1-phosphate or fructose 6-phosphate, depending on the relative availability of glucose. Increasing concentrations of both raffinose and fructose inhibited cell growth, with the degree of inhibition similar to that of glucose ( Table 1) .
Effect of sugars on MAPK activity. Subsequent studies examined the effect of glucose, raffinose, and fructose on MAPK activity. For these studies, PAEC were treated for 6-48 h with normal growth medium supplemented with 25 mM of glucose, fructose, or raffinose, and the activity of the different MAPKs was measured using an immune complex assay. Initial studies examined the effect of the sugars on JNK1 and ERK5 activity. In cells maintained for 6-48 h in normal growth medium in the absence of added sugars, there was no change over time in either JNK1 or ERK5 activity (data not shown). In contrast, JNK1 activity was increased by glucose, fructose, and raffinose, with an initial increase in JNK1 activity apparent after 12 h of treatment (Fig. 1). A peak approximately twofold increase in JNK1 activity was present after 24 h of incubation, with a return to basal kinase activity by 48 h. In contrast to this effect on JNK1 activity, only glucose had a marked effect on ERK5 activity (Fig. 2) . The effect of glucose on ERK5 activity was delayed compared with its effect on JNK1 activity, with a significant increase in activity first noted after 24 h of incubation in high-glucose medium, and a maximal 2.0-fold increase present at 48 h. Raffinose stimulated a smaller, but significant, 52% increase in ERK5 activity after 48 h of treatment.
Similar results were obtained in cells treated in the absence of FBS. For these studies, cells were maintained for 24 h in low-glucose DMEM ϩ 0.25% BSA and then treated for either 24 or 48 h with low-glucose DMEM ϩ 0.25% BSA supplemented with 25 mM of the different sugars. Treatment for 24 h with 25 mM glucose, fructose, or raffinose increased JNK1 activity 2.0 Ϯ 0.2-, 2.0 Ϯ 0.2-, and 1.8 Ϯ 0.1-fold, respectively (means Ϯ SE, n ϭ 3, P Ͻ 0.05 compared with the activity in cells maintained for 24 h in low-glucose DMEM ϩ 0.25% BSA). In contrast, after treatment for 24 h with 25 mM glucose, ERK5 activity was increased 1.9 Ϯ 0.1-fold (means Ϯ SE, n ϭ 3, P Ͻ 0.05 compared with the activity in cells maintained for 24 h in lowglucose DMEM ϩ 0.25% BSA), whereas neither raffinose nor fructose stimulated a significant increase in ERK5 activity after 24 or 48 h of treatment (data not shown).
Unlike JNK1 and ERK5 activity, p38 kinase activity, ERK1/2 phosphorylation, and ERK2 activity were not increased by treatment of the cells with normal growth medium supplemented with 25 mM glucose, raffinose, or fructose (data not shown).
Metabolic pathways that mediate the effect of glucose on MAPK activity. Having determined that glucose increases JNK1 and ERK5 activity, the contribution of different metabolic pathway(s) to the effect of glucose was examined. A well-described pathway of glucose metabolism that is active in hyperglycemic conditions is the polyol pathway, i.e., the reduction of glucose to sorbitol by aldose reductase (39) . Treatment of cells with 0.4 mM sorbinil, an inhibitor of aldose reductase, had no effect on the induction of either JNK1 or ERK5 activity by the addition of 25 mM glucose (data not shown).
Previous studies have demonstrated that incubation of endothelial cells in the presence of high glucose increases the generation of reactive oxygen species, which may alter endothelial cell growth (6, 7, 10) . Moreover, reactive oxygen species have also been shown to activate JNK1 and ERK5 in some cell types (1, 16, 23, 24) ; thus studies were performed to determine whether the generation of reactive oxygen species by PAEC incubated in hyperglycemic medium contributed to the glucose-induced increase in JNK1 and ERK5 activity. For these studies, cells were incubated for 24 h in growth medium supplemented with 25 mM glucose in the absence or presence of 10 mM N-acetylcysteine, and the activity of JNK1 and ERK5 was measured. N-acetylcysteine is an antioxidant that is a precursor of glutathione synthesis and is a free radical scavenger. Coincubation of PAEC with N-acetylcysteine had no effect on glucose-induced JNK1 activity but significantly decreased glucose-induced ERK5 activity by 64% (Fig. 3) . These data suggest that the glucose-induced increase in ERK5 activity occurred, at least in part, secondary to increased oxidative stress.
An alternative pathway of glucose metabolism that is important for glucose-induced gene expression in vascular smooth muscle cells and glucose-induced changes in insulin sensitivity is the hexosamine biosynthesis pathway (21, 32, 41) . Increased glucose flux through this pathway results in the generation of an amino sugar, glucosamine 6-phosphate, which is formed by the conversion of fructose 6-phosphate into glucosamine 6-phosphate by glutamine:fructose 6-phosphate aminotransferase (GFAT) (32) . To address the potential importance of this pathway in the glucose-induced change in JNK1 activity, an irreversible inhibitor of GFAT, azaserine, was used. For these studies, PAEC were incubated for 24 h in growth medium supplemented with 25 mM glucose in the absence or presence of 5 M azaserine. Azaserine treatment re- Fig. 2 . Effect of glucose, fructose, and raffinose on extracellular signal-regulated kinase 5 (ERK5) activity in PAEC. PAEC were plated and maintained as in Fig. 1 . ERK5 activity was determined using an immune complex assay, as described in MATERIALS AND METHODS. Kinase activity was quantified by measuring 32 P incorporation into the substrate protein myelin basic protein (MBP) with a PhosphorImager. Values represent relative 32 P incorporation into MBP using lysates from cells treated for the indicated period of time with 25 mM glucose, raffinose, or fructose compared with 32 P incorporation with lysates from cells maintained in normal growth medium, defined as 1.0. They are means Ϯ SE of 6 independent experiments. * P Ͻ 0.05 vs. level in cells maintained for the same period of time in normal growth medium; ϩ P Ͻ 0.05 vs. level in cells treated for the same period of time with either 25 mM fructose or raffinose. sulted in a significant 50% decrease in glucose-induced JNK1 activity (Fig. 4A) . In contrast, azaserine had no effect on either fructose-or raffinose-induced JNK1 activity (Fig. 4B) . These data suggest that glucose flux through the hexosamine biosynthesis pathway contributed to JNK1 activation but that the mechanism of JNK1 activation by fructose and raffinose differed, at least in part, from that of glucose.
Effect of glucosamine on PAEC. If increased flux through the hexosamine biosynthesis pathway and increased generation of glucosamine 6-phosphate account, in part, for the effects of glucose on PAEC, incubation of PAEC with glucosamine should reproduce those effects of glucose that are inhibited by azaserine, because the majority of exogenously added glucosamine is phosphorylated by hexokinase and enters the hexosamine biosynthesis pathway (31) . Initial studies examined the effect of glucosamine on JNK1 activity. For these studies, PAEC were incubated for 6-48 h with normal growth medium supplemented with either 2 or 5 mM glucosamine. Treatment with 5 mM glucosamine increased JNK1 activity, with an increase in activity noted as early as 12 h and a peak 2.4-fold increase present after 24 h of incubation (Fig.  5 ). Two mM glucosamine had no effect on JNK1 activity at 12 and 24 h and stimulated only a modest 1.5-fold increase in activity after 48 h of incubation. In contrast to its effect on JNK1 activity, glucosamine had no effect on ERK5 activity (data not shown). Subsequent studies examined the effect of glucosamine on JNK1 activity in the presence of the GFAT inhibitor azaserine. Because glucosamine enters the hexosamine biosynthesis pathway downstream of GFAT, azaserine should have no effect on glucosamine-induced effects. In PAEC incubated for 24 h in the presence of 5 mM glucosamine, JNK1 activity increased 1.8 Ϯ 0.1 and 1.8 Ϯ 0.2-fold After incubation for 24 h in the above media, cells were harvested, and JNK1 and ERK5 activity was determined using an immune complex assay. Kinase activity was quantified by measuring 32 P incorporation into the appropriate substrate protein with a PhosphorImager. Values are the relative 32 P incorporation into substrate protein by lysates from cells treated for the indicated period of time with either 10 mM N-acetylcysteine alone, 25 mM glucose alone, or 10 mM N-acetylcysteine ϩ 25 mM glucose compared with 32 P incorporation using lysates from cells maintained for the same period of time in normal growth medium, defined as 1.0. They are means Ϯ SE of 3 and 5 independent experiments for JNK1 and ERK5, respectively. * P Ͻ 0.05 vs. level in cells maintained in normal growth medium; ϩ P Ͻ 0.05 vs. level in cells treated with normal growth medium supplemented with 25 mM glucose.
(means Ϯ SE, n ϭ 5) in the presence and absence of 5 M azaserine, respectively. As expected, these data demonstrate no effect of azaserine on glucosamineinduced JNK1 activity and are consistent with the effect of azaserine on glucose-induced JNK1 activity being mediated by its effect on GFAT activity.
Subsequent studies were performed to determine whether the concentrations of glucosamine that are capable of activating JNK1 were able to reproduce the effect of glucose on PAEC growth. This was addressed by incubating cells for 24, 48, and 72 h in either normal growth medium alone or normal growth medium supplemented with 2, 4, or 5 mM glucosamine. Similarly to glucose, glucosamine inhibited cell growth in a doseand time-dependent fashion ( Table 2) . Treatment with 2 mM glucosamine had little effect on PAEC growth, but 5 mM glucosamine significantly inhibited cell growth. After 3 days of treatment, cell growth was inhibited by 76% in cells incubated in 5 mM glucosamine compared with control medium. Of note, in the studies described above, 5 mM glucose, raffinose, and fructose had a minimal effect on PAEC growth, suggesting that this effect of low concentrations of glucosamine on PAEC growth was specific.
DISCUSSION
Diabetes mellitus is a risk factor for premature atherosclerosis (9) , and although the mechanisms responsible for this diabetes-induced risk have not been completely defined, hyperglycemia appears to contribute to the increased risk (15, 22) . Previous studies have documented a variety of glucose-induced effects on endothelial cells that would promote atherogenesis, including decreased cell proliferation and apoptosis, increased production of the cytokines interleukin-1␤ and interleukin-8, and enhanced monocyte and leukocyte binding (2, 7, 10, 13, 17, 20, 26, 33, 34, 43) . In the present study, we have confirmed the finding that incubating endothelial cells in high glucose inhibits their growth. Interestingly, unlike other studies in which either mannitol or L-glucose did not reproduce the effect of glucose (10, 17, 34) , in our studies treatment of cells with either raffinose or fructose was able to reproduce the effect of glucose on cell growth. The molecular mechanisms for this growth inhibitory effect of glucose and other sugars remain obscure. A previous study suggested that an induction of transforming growth factor-␤ production by glucose with a secondary decrease in hepatocyte growth factor production accounted for the effect of glucose (34) , whereas other studies have implicated the increased production of reactive oxygen species in the effect of glucose (7, 10) . Given the fundamental role of the MAPKs in the regulation of cell growth, the present study attempted to correlate glucose-induced changes in endothelial cell growth with glucose-induced activation of the MAPKs. As expected, given the association of ERK1/2 activation with proliferative stimuli (30, 42) , neither glucose nor the other sugars had an effect on ERK1/2 phosphorylation and activity in PAEC. Only glucose had a marked effect on ERK5 activity, whereas glucose, fructose, and raffinose stimulated JNK1 activity to a similar degree, suggesting that JNK1 activation may contribute to the growth inhibitory effect of these sugars on endothelial cell growth.
The JNKs typically are activated in response to inflammation and cellular stresses, e.g., ultraviolet light, hyperosmolarity, and inhibitors of protein synthesis (23) (24) (25) . The effects of the JNKs on cell growth are complex and cell type specific. In general, however, activation of the JNKs has been associated with inhibition of cell growth and apoptosis, although association of JNK activation with cell growth also has been reported (5, 36, 40) . The effect of JNK activation on endothelial cell growth also appears to be complex. For example, an important role for JNK activation in vascular endothelial cell growth factor-induced growth of endothelial cells has been reported (37) , but a contribution of JNK activation to the induction of an inflam- PAEC were plated at a density of 5 ϫ 10 3 cells/well and maintained for 24 h in normal growth medium (low-glucose DMEM ϩ 10% FBS). Twenty-four hours after plating (day 0), cells were treated with low-glucose DMEM ϩ 10% FBS supplemented with the indicated concentration of glucosamine. Values represent relative no. of cells compared with those plated and are means Ϯ SE of results of 4 independent experiments, each done in quadruplicate. * P Ͻ 0.05 vs. relative no. of cells maintained in normal growth medium alone. Fig. 5 . Effect of glucosamine on JNK1 activity. PAEC were plated at a density of 5 ϫ 10 5 cells/75-cm 2 plate, and, 24 h after plating, medium was replaced with either normal growth medium or growth medium supplemented with 2 mM or 5 mM glucosamine. After incubation in the above media for the indicated period of time, cells were harvested, and JNK1 activity was determined using an immune complex assay. Kinase activity was quantified by measuring 32 P incorporation into GST-c-Jun81 with a PhosphorImager. Values represent the relative 32 P incorporation into GST-c-Jun81 by lysates from cells treated for the indicated period of time with either 2 or 5 mM glucosamine compared with 32 P incorporation by lysates from cells maintained for the same period of time in normal growth medium. They are means Ϯ SE of 3 independent experiments. * P Ͻ 0.05 vs. level in cells maintained in normal growth medium;
ϩ P Ͻ 0.05 vs. level in cells maintained in normal growth medium supplemented with 2 mM glucosamine. matory response by tumor necrosis factor-␣ in endothelial cells and to apoptosis in mannitol-and ceramidetreated as well as serum-starved endothelial cells also has been reported (11, 29, 38) . Interestingly, in the present study, the temporal sequences of JNK1 activation and the inhibition of cell growth by glucose, fructose, and raffinose differed, i.e., the increase in JNK1 activity had dissipated by 48 h, whereas the inhibition of cell growth was most prominent after 48 and 72 h of treatment with these sugars. These data suggest that JNK activation may be important early in the inhibition of cell growth and/or that JNK activation is an early part of or initiates a program of events associated with the inhibition of cell growth. In the absence of specific inhibitors of the JNK pathway, the role of JNK activation in endothelial cell growth cannot be directly assessed.
Interestingly, despite the ability of glucose, fructose, and raffinose to activate JNK1, the mechanism of action of the sugars differed, at least in part. Azaserine, a GFAT inhibitor that inhibits glucose flux through the hexosamine biosynthesis pathway, decreased glucoseinduced JNK1 activity by 50% but had no effect on JNK1 activation by fructose or raffinose. This result suggested that increased flux through the hexosamine pathway contributes to glucose-induced JNK1 activation. Consistent with this observation, glucosamine, which is a direct precursor of the downstream product of the hexosamine biosynthesis pathway, glucosamine 6-phosphate, also increased JNK1 activity in the PAEC. Like the other sugars that activated JNK1, glucosamine was able to inhibit cell growth. Together, these observations suggest that increased flux through the hexosamine biosynthesis pathway accounts, in part, for glucose-induced JNK1 activity and, possibly, inhibition of cell growth, although a contribution of osmotic effects cannot be ruled out.
Besides JNK1, glucose activated an additional member of the MAPK family, ERK5. ERK5 is a recently identified novel member of the MAPK family that is activated by stresses, such as oxidative stress and hyperosmolarity, but is also activated by receptor tyrosine kinases (1, 16) . In HeLa cells, ERK5 was shown to be important for the growth-promoting effects of epidermal growth factor (18) . In contrast to JNK1, a marked increase in ERK5 activity was stimulated only by high glucose, and its activation by glucose was inhibited by an antioxidant, N-acetylcysteine. Together with the lack of effect of glucosamine on ERK5 activity, these data suggest that ERK5 activation occurs via a metabolic pathway distinct from that which stimulates JNK1 activity. The inhibition of glucoseinduced ERK5 activation by an antioxidant is consistent with the previous observation that H 2 O 2 activates ERK5 in endothelial cells (1) . In addition to H 2 O 2 , shear stress also has been shown to increase ERK5 activity in endothelial cells (44) . The functional consequence of ERK5 activation by oxidative and shear stress in endothelial cells is not known. Similarly, the functional consequences of the ERK5 activation by high glucose in endothelial cells are not known; however, again, because only high glucose increased ERK5 activity, it is likely that it mediates glucose-induced effects other than inhibition of cell growth.
The effect of glucose on MAPK activity has been examined previously in two different cell types, pancreatic ␤-cells, which are programmed to respond to glucose, and vascular smooth muscle cells (VSMC). In pancreatic ␤-cells, glucose activates primarily ERK1 and -2 but also has a modest effect on p38 kinase activity (4, 19, 28) . Activation of the ERKs and, possibly, p38 kinase in ␤-cells appears to be important for glucose-induced expression of the insulin gene (3, 28) . In VSMC, high glucose stimulates a modest increase in ERK1 and -2 activity and has a more marked effect on p38 kinase activity via a pathway dependent on activation of protein kinase C-␦ (14) . In contrast, glucose has no effect on JNK activity in VSMC (14) . The present study is the first to examine the effect of glucose on MAPK activity in endothelial cells. Interestingly, the pattern of MAPK activation by glucose differed markedly in endothelial cells and VSMC. In endothelial cells, glucose increased JNK and ERK5 activity but had no effect on either ERK or p38 kinase activity. The activation of different MAPK isoforms by high glucose in VSMC and endothelial cells is consistent with the disparate effect of glucose on the growth of these two cell types. In contrast to endothelial cells, glucose stimulates the growth of VSMC (10, 12, 34, 35, 45, 46) . In summary, the present studies have confirmed previous findings demonstrating an inhibitory effect of glucose on endothelial cell growth and, for the first time, have correlated these changes in cell growth with activation of the MAPKs by glucose. The marked correlation between the ability of several sugars to inhibit endothelial cell growth and activate JNK1 suggests that JNK activation may contribute to the modulation of endothelial cell growth by different sugars, whereas the more specific activation of ERK5 by high glucose suggests that it may mediate other effects of glucose in endothelial cells. Future studies will be needed to define the role of JNK activation in glucose-mediated inhibition of endothelial cell growth and the functional consequences of increased ERK5 activity.
